Aeglea Biotherapeutics was ranked as the fourth worst performing IPO of this year, with negative returns of 38.8 percent.The cancer biotech raised $50 million in April by offering 5 million shares at $10 per share, below the expected range of $16 to $18 per share. The Texas-based biotechnology company is listed on the Nasdaq Global Market under the symbol “AGLE”.